Dr. Jeffrey Lieberman, author of the new book “Shrinks: The Untold Story of Psychiatry,” told “CBS This Morning” hosts Charlie Rose and Gayle King that he was driven to write the book by the fact that “the old attitudes” of stigma prevail. “I became so upset that millions of people continue to suffer from the symptoms of mental illness either they’re ashamed or embarrassed to reach out for treatment, or they don’t know how to find it.”
Dr. Lieberman said “lack of awareness and prejudice” keep people who could be treated from getting effective treatments that simply weren’t available just decades ago, as recently as the 1950s, when, he said, “there was little that any doctor could do.”
Hey Jeffrey, Just looking at your crazy sensationalist, scare-mongering interview on CBS news.
I’d like to ask you where do you get the statistic that 18.6% of Americans suffer from ‘mental illness’. This is an outrageous statement, that’s like saying almost one in 5 people in the US are currently mentally ill. Where do these figures come from Jeffrey? It seems to me, that year on year, decade upon decade, psychiatry increases its arbitrary guesstimates of the prevalence of ‘mental illness’ in society. More diagnosis means more treatment. If only we could get more and more people on psychiatric drugs Jeffrey, psychiatric business would be even busier wouldn’t it? More clients in the system, more caught in the psychiatric net equals more business, more drugs, more money, more sales. Win-Win for psychiatry and the pharmaceutical companies but not so much for the patient on the psych-drug merry go round though is it? It’s really just a descent into worsening mental/emotional and physical health for those in the psych-system isn’t it? That’s something the APA doesn’t advertise though…
I was on your psych-drug merry go round, and I got off it Jeffrey, so your propaganda doesn’t wash with people like me. You just can’t bullshit people like me, sorry about that.
I noticed that you failed to tell the viewers, or the talk show hosts on CBS, about your disturbingly vast collection of potential conflicts of interests with pharmaceutical companies over the years.
As I said before Jeffrey, how does it feel to have the hand of Big Pharma shoved so far up there?:
In 2006, Lieberman co-signed a letter to the editor of The Wall Street Journal with about thirty other doctors. With this, he disclosed honoraria, consulting fees, research grant support from AstraZeneca, Bristol-Myers Squibb, Upjohn Pharmacia, Novartis, Eli Lilly, Janssen, Pfizer, Hoechst AG, and AstraZeneca. He also listed as corporate speakers bureaus AstraZeneca, Janssen, Eli Lilly, and Pfizer.
Lieberman disclosed in 2007 in the journal Primary Psychiatry that he was a consultant to Eli Lilly and Pfizer. He was on the advisory boards of AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck,Organon, and Pfizer. He has a patent from Repligen Corporation. Lieberman received research support from Acadia, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, Organon, and Pfizer. In 2009, Lieberman disclosed grants from Allon, Forest Laboratories, Merck, Pfizer, AstraZeneca, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Otsuka, Solvay, and Wyeth to the American College of Neuropsychopharmacology for their annual meeting in which he participated.
In 2011, his disclosure at Medscape of relevant financial relationships says he served on the advisory board of Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Eli Lilly, Pierre Fabre, and Psychogenics, and that he received research grants from Allon Therapeutics, GlaxoSmithKline, Ortho-McNeil-Janssen, Merck, Novartis, Pfizer, Sepracor, and Targacept.
He also disclosed in 2013, as a member of the psychiatry editorial board at Medscape, that he received research grants from Allon, Novartis, Sepracor, and Targacept; and he served on the advisory boards at Bioline, Intra-Cellular Therapies, Pierre Fabre and Psychogenics. In additional disclosures at Medscape in 2013, he received research grants from Allon, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Pfizer, Psychogenics, Hoffmann-La Roche, Sepracor, and Targacept, and he served on the advisory board of Alkermes, Bioline, Intra-Cellular Therapies, Pierre Fabre, and Psychogenics.